Ruparib (Rucaparib) Tablet

Description

Description

This page contains brief details about the drug rucaparib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Rucaparib is an anticancer drug that belongs to the class of medications called PARP (poly ADP-ribose polymerase) inhibitors. FDA approved this medicine on December 19, 2016, to treat certain types of cancers.

Mechanism of Action of Rucaparib

Rucaparib is an inhibitor of poly Adenosine diphosphate-ribose polymerase enzymes, including PARP-1, PARP-2, and PARP-3, which play a role in DNA repair. It blocks an enzyme that repairs damaged DNA in the cancer cells, resulting in their death.

Uses of Rucaparib

Rucaparib is an orally available prescription drug. It is used to help maintain the response to other treatments for certain types of ovarian cancer, fallopian tube (a tube that transports eggs released by the ovaries to the uterus), and primary peritoneal (layer of tissue that lines the abdomen) cancer that has reoccurred in adults who have previously completely responded or partially responded to other chemotherapy treatments.

It is also used to treat certain types of cancer in people with specific gene (BRCA) changes who have received treatment with at least two other chemotherapy treatments. It is also indicated as maintenance therapy immediately after chemotherapy which has caused the tumor to shrink.

Rucaparib Dosage available

It is an orally available antineoplastic drug. The medicine is available as 200mg, 250mg, and 300mg tablets. Your doctor will decide the dose and duration of Rucaparib based on the disease condition and other factors. Always take this medicine as prescribed by your doctor. Take the tablet at the same time, with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with water.